Astellas and Medivation in Pact for Prostate Cancer Drug
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 11 (Table of Contents)
Published: 2 Nov-2009
DOI: 10.3833/pdr.v2009.i11.1266 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Astellas has signed an agreement to co-develop and commercialize MDV3100, a drug for the treatment of prostate cancer developed by Medivation, which is in Phase III clinical trials...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS